Intelligence · Clinical Pipeline

Infectious disease R&D Pipeline

Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Programs
1,126

Quick answer

Infectious disease: NovaPharmaNews indexes 1,126 infectious disease clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Top sponsors

Page 8 of 24

  1. ARO-HSD Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial
  2. ASC22

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    phase 2 small molecule completed

    1 trial
  3. AT-527

    Atea Pharmaceuticals

    Hepatitis C

    phase 2 small molecule completed

    1 trial
  4. AT-527

    Atea Pharmaceuticals

    COVID-19

    phase 2 small molecule terminated

    2 trials
  5. AT-777

    Atea Pharmaceuticals

    Hepatitis C

    phase 2 small molecule terminated

    1 trial
  6. AVI-4065 Injection

    Sarepta Therapeutics

    Hepatitis C

    phase 2 small molecule terminated

    1 trial
  7. Alvelestat

    Mereo BioPharma Group plc

    Covid19

    phase 2 small molecule completed

    1 trial
  8. Analogs, Prostaglandin E1

    Vera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial
  9. Anti-PD-1 antibody

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    phase 2 small molecule active

    1 trial
  10. Antibody UB-421

    United Therapeutics Europe Ltd

    HIV-1 Infection in Adults

    phase 2 small molecule completed

    1 trial
  11. Aprepitant injectable emulsion

    Heron Therapeutics

    COVID-19

    phase 2 small molecule terminated

    1 trial
  12. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial
  13. BEVACIZUMAB

    Pari Pharma GmbH

    Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.

    phase 2 small molecule active

    1 trial
  14. BMS-955176

    ViiV Healthcare B.V.

    HIV Infections

    phase 2 small molecule terminated

    1 trial
  15. BRII-179

    Vir Biotechnology

    For Treatment of Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial
  16. BRII-835 (VIR-2218)

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial
  17. Bacteriophage

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 small molecule terminated

    1 trial
  18. Bacteriophage Therapy

    Adaptive Biotechnologies Corp

    Urinary Tract Infection Bacterial

    phase 2 mab terminated

    1 trial
  19. Bamlanivimab

    Vir Biotechnology

    COVID-19

    phase 2 small molecule completed

    1 trial
  20. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings

    phase 2 other terminated

    1 trial
  21. Behavioral Drug and Risk Counseling (BDRC)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Risk Behaviors

    phase 2 other completed

    1 trial
  22. Bemnifosbuvir

    Atea Pharmaceuticals

    Chronic Hepatitis C Virus

    phase 2 small molecule completed

    1 trial
  23. Benznidazole

    BRIGHT MINDS BIOSCIENCES INC.

    Trypanosoma Cruzi Infection

    phase 2 small molecule completed

    1 trial
  24. Bisphosphocin Nu-3

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial
  25. Bovine colostrum

    Hospital Authority, Hong Kong

    Severe Alcoholic Hepatitis in 'Extremis'- Defined by mDF>54

    phase 2 other completed

    1 trial
  26. Brincidofovir

    Jazz Pharmaceuticals Ireland Limited

    Cytomegalovirus Infection

    phase 2 small molecule completed

    1 trial
  27. Budigalimab, Placebo for Budigalimab (ABBV-181) - 0.9% Sodium Chloride or DILUENT, ABBV-382, Placebo for ABBV-382 Solution for Infusion

    AbbVie Deutschland GmbH & Co. KG

    HIV infection

    phase 2 small molecule active

    1 trial
  28. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial
  29. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial
  30. BufferGel

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 small molecule completed

    1 trial
  31. Busulfan Koanaa 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GRANOCYTE 34 Millions UI/ml, poudre et solvant pour solution injectable / perfusion, Autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene, Plerixafor Accord 20 mg/ml solution for injection

    Fondazione Telethon ETS

    transfusion-dependent beta-thalassemia

    phase 2 small molecule active

    1 trial
  32. CAP-1002

    CAPRICOR THERAPEUTICS, INC.

    Covid19

    phase 2 mab completed

    1 trial
  33. CERC-002

    Avalo Therapeutics

    COVID-19 Pneumonia

    phase 2 small molecule completed

    1 trial
  34. CF 102

    Can-Fite BioPharma

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial
  35. CF102

    Can-Fite BioPharma

    Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial
  36. CHRONVAC-C®

    INOVIO PHARMACEUTICALS, INC.

    Chronic Hepatitis C Virus Infection

    phase 2 small molecule active

    1 trial
  37. COVAXIN(BBV152)

    Biotech Pharmaceutical Co.,

    Corona Virus Infection

    phase 2 mab completed

    1 trial
  38. COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab terminated

    1 trial
  39. COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    1 trial
  40. COVID-19 Vaccine HIPRA

    Hipra Human Health S.L.

    COVID-19

    phase 2 mab completed

    1 trial
  41. CP101

    Finch Therapeutics Group

    Clostridium Difficile Infection

    phase 2 mab completed

    1 trial
  42. CRV431 75mg

    Hepion Pharmaceuticals

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial
  43. CSG452 (Tofogliflozin) placebo, pemafibrate, K-877 ER (Pemafibrate) placebo, TOFOGLIFLOZIN

    The George Institute

    Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

    phase 2 small molecule active

    1 trial
  44. CT-011

    Teva Pharma GmbH

    Chronic Hepatitis C

    phase 2 small molecule terminated

    1 trial
  45. CYSTAGON 150 mg hard capsules

    The George Institute

    Infectious diseases of respiratory system (COVID-19)

    phase 2 small molecule active

    1 trial
  46. Cefiderocol

    Shionogi B.V.

    Gram-negative Bacterial Infections

    phase 2 small molecule completed

    1 trial
  47. Ceftriaxone 1000mg + doxycycline 100 mg

    Hong Kong Baptist University

    Neisseria Gonorrhoeae Infection

    phase 2 small molecule completed

    1 trial
  48. Cemiplimab

    Regeneron UK Limited

    Hepatitis B Virus

    phase 2 mab terminated

    1 trial

Frequently asked questions

How many infectious disease pipeline programs are tracked?

1,126 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs